XNCR Key Statistics, Chart & Performance
The current stock price of XNCR is 17.32 USD. In the past month the price increased by 22.58%. In the past year, price decreased by -32.34%.
XNCR Latest News, Press Relases and Analysis
XNCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About XNCR
Company Profile
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 250 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Company Info
XENCOR INC
465 N. Halstead St., Suite 200
Pasadena CALIFORNIA 91016 US
CEO: Bassil I. Dahiyat
Employees: 250
Phone: 16263055900
XENCOR INC / XNCR FAQ
Can you describe the business of XENCOR INC?
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 250 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
What is the current price of XNCR stock?
The current stock price of XNCR is 17.32 USD. The price decreased by -0.35% in the last trading session.
What is the dividend status of XENCOR INC?
XNCR does not pay a dividend.
How is the ChartMill rating for XENCOR INC?
XNCR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting XNCR stock to perform?
19 analysts have analysed XNCR and the average price target is 28.47 USD. This implies a price increase of 64.36% is expected in the next year compared to the current price of 17.32.
What is the employee count for XNCR stock?
XENCOR INC (XNCR) currently has 250 employees.
What is XENCOR INC worth?
XENCOR INC (XNCR) has a market capitalization of 1.24B USD. This makes XNCR a Small Cap stock.
XNCR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to XNCR. When comparing the yearly performance of all stocks, XNCR is one of the better performing stocks in the market, outperforming 91.56% of all stocks.
XNCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XNCR. XNCR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
XNCR Financial Highlights
Over the last trailing twelve months XNCR reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 44.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.97% | ||
| ROE | -22.19% | ||
| Debt/Equity | 0.14 |
XNCR Forecast & Estimates
19 analysts have analysed XNCR and the average price target is 28.47 USD. This implies a price increase of 64.36% is expected in the next year compared to the current price of 17.32.
For the next year, analysts expect an EPS growth of 26.65% and a revenue growth 119.19% for XNCR